Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland
- PMID: 29928168
- PMCID: PMC6006633
- DOI: 10.1159/000489900
Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland
Abstract
Introduction: Bacterial contamination of platelet concentrates (PCs) has been identified as the most prevalent transfusion-associated infectious risk. To prevent PC-related septic transfusion reactions, the Intercept® pathogen inactivation procedure was introduced for all PCs in Switzerland in 2011.
Methods: Based on numbers of transfused units and mandatorily reported adverse events with high imputability, we compare the risks associated with transfusion of conventional PCs (cPCs) and pathogen-inactivated PCs (PI-PCs).
Results: From 2005 to 2011, a total of 158,502 cPCs have been issued in Switzerland, and 16 transfusion-transmitted bacterial infections (including 3 fatalities) were reported. This corresponds to a morbidity and mortality rate of ca. 1:9,900 and 1:52,800, respectively. From 2011 to 2016, a total of 205,574 PI-PCs have been issued, and no transfusion-transmitted bacterial infection was reported. Despite continuously increasing transfusion reaction rates per 1,000 RBC and plasma issued between 2008 and 2016, we observed reductions of 66% for life-threatening and fatal reactions and of 26% for all high-imputability transfusion reactions related to PI-PCs as compared to cPCs. No increased rates of bleeding or clinical observations of ineffectiveness of PI-PCs have been reported. After implementation of PI-PCs, the annual increase in platelet usage per 1,000 inhabitants decelerated.
Discussion: Swiss hemovigilance data confirm a favorable safety profile of the nationwide introduced Intercept pathogen inactivation procedure and its reliable prevention of septic transfusion reactions and fatalities due to bacterially contaminated PCs.
Keywords: Blood safety; Platelet concentrates; Transfusion reaction; Transfusion risks; Transfusion-associated infections.
References
-
- Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion. 2007;47:421–429. - PubMed
-
- Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev. 2005;19:259–272. - PubMed
-
- Swissmedic Haemovigilance Annual Reports (Report 2009) www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung... (last accessed May 9, 2018)
-
- Swissmedic, Authorised Procedures. / www.swissmedic.ch/swissmedic/de/home/services/zugelassene-verfahren-und-... (last accessed May 9, 2018)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous